Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Terpos

Showing results (71-80 of 101) with videos related to

Pageof 11
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 19, 2007
VAD-doxil versus VAD-doxil plus thalidomide as initial treatment for multiple myeloma: results of a multicenter randomized trial of the Greek Myeloma Study GroupK Zervas, D Mihou, E Katodritou, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 10, 2011
The International Scoring System (ISS) for multiple myeloma remains a robust prognostic tool independently of patients' renal functionM A Dimopoulos, E Kastritis, E Michalis, et al.
Leukemia|May 8, 2009
International myeloma working group consensus statement and guidelines regarding the current role of imaging techniques in the diagnosis and monitoring of multiple MyelomaM Dimopoulos, E Terpos, R L Comenzo, et al.
British Journal of Cancer|November 22, 2012
VEGF directly suppresses activation of T cells from ascites secondary to ovarian cancer via VEGF receptor type 2N G Gavalas, M Tsiatas, O Tsitsilonis, et al.
Leukemia|February 20, 2009
Improved survival of patients with multiple myeloma after the introduction of novel agents and the applicability of the International Staging System (ISS): an analysis of the Greek Myeloma Study Group (GMSG)E Kastritis, K Zervas, A Symeonidis, et al.
Blood Cancer Journal|October 8, 2016
High levels of periostin correlate with increased fracture rate, diffuse MRI pattern, abnormal bone remodeling and advanced disease stage in patients with newly diagnosed symptomatic multiple myelomaE Terpos, D Christoulas, E Kastritis, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 26, 2009
The use of bisphosphonates in multiple myeloma: recommendations of an expert panel on behalf of the European Myeloma NetworkE Terpos, O Sezer, P I Croucher, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 21, 2013
Significant improvement in the survival of patients with multiple myeloma presenting with severe renal impairment after the introduction of novel agentsM A Dimopoulos, S Delimpasi, E Katodritou, et al.
Seminars in Hematology|April 26, 2023
Report of consensus panel 5 from the 11th international workshop on Waldenstrom's macroglobulinemia on COVID-19 prophylaxis and managementE Terpos, A R Branagan, R García-Sanz, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 7, 2021
Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up<sup>†</sup>M A Dimopoulos, P Moreau, E Terpos, et al.
Pageof 11

Showing results (71-80 of 101) with videos related to

Sort By:
Pageof 11
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 19, 2007
VAD-doxil versus VAD-doxil plus thalidomide as initial treatment for multiple myeloma: results of a multicenter randomized trial of the Greek Myeloma Study GroupK Zervas, D Mihou, E Katodritou, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 10, 2011
The International Scoring System (ISS) for multiple myeloma remains a robust prognostic tool independently of patients' renal functionM A Dimopoulos, E Kastritis, E Michalis, et al.
Leukemia|May 8, 2009
International myeloma working group consensus statement and guidelines regarding the current role of imaging techniques in the diagnosis and monitoring of multiple MyelomaM Dimopoulos, E Terpos, R L Comenzo, et al.
British Journal of Cancer|November 22, 2012
VEGF directly suppresses activation of T cells from ascites secondary to ovarian cancer via VEGF receptor type 2N G Gavalas, M Tsiatas, O Tsitsilonis, et al.
Leukemia|February 20, 2009
Improved survival of patients with multiple myeloma after the introduction of novel agents and the applicability of the International Staging System (ISS): an analysis of the Greek Myeloma Study Group (GMSG)E Kastritis, K Zervas, A Symeonidis, et al.
Blood Cancer Journal|October 8, 2016
High levels of periostin correlate with increased fracture rate, diffuse MRI pattern, abnormal bone remodeling and advanced disease stage in patients with newly diagnosed symptomatic multiple myelomaE Terpos, D Christoulas, E Kastritis, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 26, 2009
The use of bisphosphonates in multiple myeloma: recommendations of an expert panel on behalf of the European Myeloma NetworkE Terpos, O Sezer, P I Croucher, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 21, 2013
Significant improvement in the survival of patients with multiple myeloma presenting with severe renal impairment after the introduction of novel agentsM A Dimopoulos, S Delimpasi, E Katodritou, et al.
Seminars in Hematology|April 26, 2023
Report of consensus panel 5 from the 11th international workshop on Waldenstrom's macroglobulinemia on COVID-19 prophylaxis and managementE Terpos, A R Branagan, R García-Sanz, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 7, 2021
Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up<sup>†</sup>M A Dimopoulos, P Moreau, E Terpos, et al.
Pageof 11